MIMA Pilot Study: MIcrostructure of the Medial Temporal Lobe in Early Alzheimer's Disease (MIMA-P)

Rennes University Hospital

Status: Enrolling

Conditions: Alzheimer Disease, Early Onset

Treatments: Diagnostic Test: high-resolution diffusion MRI

Study type: Interventional

Funder types: Other

Identifiers

NCT06099587

35RC23_8900_MIMA-P

Details and patient eligibility

About

Patients with Mild Cognitive Impairment (MCI) or Subjective Cognitive Decline (SCD) may or may not develop Alzheimer's disease (AD) dementia. Yet identifying patients at risk is crucial: delaying the onset of the disease by 5 years could reduce prevalence by 50%. To achieve this, we need affordable biomarkers combined with clinically meaningful assessment tools. Current approaches (cognition, imaging or Tau and Amyloid peptide assays) lack precision or specificity (e.g., age-related memory deficits) and involve invasive and costly procedures, sometimes inaccessible in France (e.g., the "AT(N)" framework). Recently, quantitative diffusion MRI (dMRI) has identified in-vivo gray matter microstructural changes linked to hyperphosphorylated Tau protein, which are of great diagnostic value. Still, we ignore whether and how these changes are responsible for early memory impairment in AD. The MIMA-P project will combine multi-compartment models of the high-resolution diffusion signal with a cognitive assessment of memory based on recent models of medial temporal lobe function to assess the relevance of a new affordable, rapid and non-invasive early marker of the disease.

Full description

The study will combine multi-compartment models (e.g. Archer et al., 2020; Parker et al., 2020) of high-resolution diffusion MRI within medial temporal lobes regions of interest defined through the ASHS algorithm (Yushkevich et al., 2015), with theoretically driven cognitive assessment medial temporal lobes functions. The '4 mountains test' and the 'Memory entities' test will allow specific probing of hippocampal and rhinal cortices functions, respectively (Hartley et al., 2007; Besson et al., 2020).

25 patients with 'subjective cognitive decline-plus' (hereafter 'SCD', criteria of Jessen et al., 2014) and 25 patients with mild neurocognitive impairment due to Alzheimer's disease (hereafter 'MCI', criteria of Albert et al., 2011) matched for gender, socio-professional category and level of education. The 25 healthy volunteers required have already been included in a different study.

Enrollment: 50 estimated patients

Sex: All

Ages: 50 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• aged between 50 and 80
• native French speaking
• right-handed
• with a level of education equal to or higher than the Certificat d'Etudes Primaires (primary school leaving certificate)
• free of any medical or psychiatric condition likely to interfere with cognition, other than a diagnosis of SCD / MCI
• affiliated with a social security scheme
• having received oral and written information abou the protocol and having signed a consent form to participate in this research
• patients with 'subjective cognitive decline-plus' (hereafter 'SCD', criteria of Jessen et al., 2014) or patients with mild neurocognitive impairment due to Alzheimer's disease (hereafter 'MCI', criteria of Albert et al., 2011)

Exclusion criteria

• contraindications to MRI : Abdominal circumference + upper limbs stuck to the body > 200 cm; Implantable pacemaker or defibrillator; Neurosurgical clips; Cochlear implants ; Neural or peripheral stimulator; Intra-orbital or encephalic metallic foreign bodies; Endoprostheses fitted less than 4 weeks ago and osteosynthesis devices fitted less than 6 weeks ago; Claustrophobia.
• sensory deficit interfering with experimental tests
• pregnant or breast-feeding women
• adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty
• 7-items modified Hachinski ischemic score >2 (Hachinski et al., 2012)
• Dementia (McKhann et al., 2011)

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

50 participants in 2 patient groups

SCD+

Experimental group

Description:

Patients with subjective cognitive decline-plus due to Alzheimer's disease (or "DCS" in french)

Treatment:

Diagnostic Test: high-resolution diffusion MRI

MCI

Experimental group

Description:

Patients with mild neurocognitive impairment due to Alzheimer's disease (or "TCL" in french)

Treatment:

Diagnostic Test: high-resolution diffusion MRI